Back to Search Start Over

Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study

Authors :
Emma J Crosbie
B Russell
Andrew R Clamp
Amy Hawarden
Richard J. Edmondson
Mary Ellen Gee
Fatima Kayali
Source :
BMC Cancer, Hawarden, A, Russell, B, Gee, M E, Skayali, F, Clamp, A, Crosbie, E & Edmondson, R 2021, ' Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study ', BMC Cancer . https://doi.org/10.1186/s12885-021-08019-9, BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

Background Despite improvements in median survival some patients with advanced ovarian cancer die within 100 days of diagnosis; the reasons for which remain poorly understood. Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways. Methods A nested case comparison study was used to examine differences between patients with high grade serous ovarian/fallopian tube cancer who died within 100 days (n = 28) compared to a comparison group of patients matched for histology and including any survival greater than 100 days (n = 134). Results Cases and comparison patients had similar ages, BMI, ACE-27, deprivation indices, and distribution of disease on CT. There were no significant delays in time to diagnosis or treatment (p = 0.68) between the groups. However, cases had lower serum albumin, haemoglobin and higher platelet counts than matched comparison patients (p P = 0.006). Conclusion Patients who die rapidly after a diagnosis of ovarian cancer are only slightly older and have similar pre treatment frailty compared to patients whose survival approaches the median. However they do appear to undergo greater physiological compromise as a result of their disease.

Details

ISSN :
14712407
Volume :
21
Database :
OpenAIRE
Journal :
BMC Cancer
Accession number :
edsair.doi.dedup.....2c667c1f61fb4614da1649c95a193dcc
Full Text :
https://doi.org/10.1186/s12885-021-08019-9